Retina Research
Currently Recruiting
Gene Therapy via One-Time Intravitreal Injection for Wet Age-Related Macular Degeneration
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults With Macular Neovascularization Secondary to Age-Related Macular Degeneration
A Phase 3 study to evaluate the safety and efficacy of a single intravitreal injection of 4D-150, an AAV-based retinal gene therapy to induce local intraocular anti-VEGF production.
Control arm receives Eylea (aflibercept) q8weeks after 3 loading doses. Treatment arm also receives 3 loading doses of Eylea in addition to investigational drug, and then subsequent anti-VEGF injections only if needed.
- Subjects age ≥ 50 years with macular neovascularization secondary to age-related macular degeneration
- Subfoveal or juxtafoveal CNV with subfoveal subretinal leakage
- CST <500 microns
- 20/32 – 20/320 in the study eye and 20/200 or better in the fellow eye
- Study duration: 2 years
- Recruiting subjects who have never received treatment for neovascular AMD (treatment-naive)
Those that qualify for clinical trials will receive all study-related care including testing, procedures, and medication from a board-certified physician at no cost and may receive compensation for time and travel.